Novo Nordisk A/S - share repurchase programme

SelfRugger

2026-02-28 20:58:50

This is a paid press release. Contact the press release distributor directly with any inquiries.

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S

Mon, February 23, 2026 at 9:24 PM GMT+9 2 min read

In this article:

NVO

-2.13%

Novo Nordisk A/S

Bagsværd, Denmark, 23 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.

Since the announcement 16 February 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	1,750,000		533,796,640
16 February 2026	200,000	307.89	61,578,124
17 February 2026	200,000	309.73	61,945,457
18 February 2026	200,000	309.63	61,925,026
19 February 2026	200,000	309.29	61,858,675
20 February 2026	200,000	304.47	60,893,513
Accumulated under the programme	2,750,000		841,997,435

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 20,139,799 B shares of DKK 0.10 as treasury shares, corresponding to 0.5% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 20 February 2026, Novo Nordisk has since 4 February 2026 repurchased a total 2,750,000 B shares at an average share price of DKK 306.18 per B share equal to a transaction value of DKK 841,997,435.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube_._

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 [email protected]	Liz Skrbkova (US) +1 609 917 0632 [email protected]
Investors:
Michael Novod +45 3075 6050 [email protected]	Jacob Martin Wiborg Rode +45 3075 5956 [email protected]
Max Ung +45 3077 6414 [email protected]	Sina Meyer +45 3079 6656 [email protected]
Alex Bruce +45 34 44 26 13 [email protected]	Christoffer Sho Togo Tullin +45 3079 1471 [email protected]
Frederik Taylor Pitter +1 609 613 0568 [email protected]

Company Announcement No 14/2026

Story continues

Attachments

CA260223 safe harbour transaction details

CA260223 safe harbour

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.